National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2017 (No. 2) (PB 20 of 2017) (Cth)

PB 20 of 2017

National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2017 (No. 2)

National Health Act 1953

___________________________________________________________________________

I, JULIANNE QUAINE, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health and Minister for Sport, make this Amendment Instrument under subsection 100(2) of the National Health Act 1953.

Dated 30 March 2017

Julianne Quaine

Assistant Secretary

Pharmaceutical Access Branch

Pharmaceutical Benefits Division

Department of Health

___________________________________________________________________________

Part 1        Preliminary

1                  Name of Instrument

(1)This instrument is the National Health (Highly specialised drugs program) Special Arrangement Amendment Instrument 2017 (No. 2).

(2)This instrument may also be cited as PB 20 of 2017.

2              Commencement

This instrument commences on 1 April 2017.

3              Amendment

The Schedule amends the National Health (Highly specialised drugs program) Special Arrangement 2010 (PB 116 of 2010).

Schedule – Amendments

Schedule

National Health (Highly specialised drugs program) Special Arrangement 2010 (PB 116 of 2010)

1. Schedule 1, entry for Apomorphine

Substitute:

Apomorphine	Injection containing apomorphine hydrochloride 10 mg in 1 mL	Injection	Apomine	PF	EMP	C4833 C4860	360	5	D
Injection containing apomorphine hydrochloride 20 mg in 2 mL	Injection	Movapo	TD	EMP	C4833 C4860	360	5	D
Injection containing apomorphine hydrochloride 50 mg in 5 mL	Injection	Movapo	TD	EMP	C4833 C4860	180	5	D
Injection containing apomorphine hydrochloride 100 mg in 20 mL	Injection	Apomine Solution for Infusion	PF	EMP	C4860 C6813	90	5	D
Solution for subcutaneous infusion containing apomorphine hydrochloride 50 mg in 10 mL pre-filled syringe	Injection	Movapo PFS	TD	EMP	C4833 C4860	180	5	D

1. Schedule 1, entry for Entecavir

Substitute:

Entecavir	Tablet 0.5 mg (as monohydrate)	Oral	Baraclude	BQ	EMP	C4993 C5036	60	5	D
ENTAC	LR	EMP	C4993 C5036	60	5	D
Entecavir Amneal	EA	EMP	C4993 C5036	60	5	D
Entecavir APOTEX	TX	EMP	C4993 C5036	60	5	D
Entecavir GH	GQ	EMP	C4993 C5036	60	5	D
Entecavir Mylan	AF	EMP	C4993 C5036	60	5	D
ENTECAVIR RBX	RA	EMP	C4993 C5036	60	5	D
Entecavir Sandoz	SZ	EMP	C4993 C5036	60	5	D
ENTECLUDE	RW	EMP	C4993 C5036	60	5	D
Tablet 1 mg (as monohydrate)	Oral	Baraclude	BQ	EMP	C5037 C5044	60	5	D
ENTAC	LR	EMP	C5037 C5044	60	5	D
Entecavir Amneal	EA	EMP	C5037 C5044	60	5	D
Entecavir APOTEX	TX	EMP	C5037 C5044	60	5	D
Entecavir GH	GQ	EMP	C5037 C5044	60	5	D
Entecavir Mylan	AF	EMP	C5037 C5044	60	5	D
ENTECAVIR RBX	RA	EMP	C5037 C5044	60	5	D
Entecavir Sandoz	SZ	EMP	C5037 C5044	60	5	D
ENTECLUDE	RW	EMP	C5037 C5044	60	5	D

1. Schedule 1, entry for Epoprostenol                          Substitute:

Epoprostenol	Powder for I.V. infusion, 500 micrograms (as sodium) infusion administration set	Injection	Flolan Kit	GK	EMP	C6123 C6734 C6748 C6762 C6763	1	0	D
Powder for I.V. infusion 500 micrograms (as sodium)	Injection	Veletri	AT	EMP	C6123 C6734 C6748 C6762 C6763	1	0	D
Powder for I.V. infusion 500 micrograms (as sodium) with 2 vials diluent 50 mL	Injection	Flolan	GK	EMP	C6123 C6734 C6748 C6762 C6763	1	0	D
Powder for I.V. infusion, 1.5 mg (as sodium) infusion administration set	Injection	Flolan Kit	GK	EMP	C6123 C6734 C6748 C6762 C6763	1	0	D
Powder for I.V. infusion 1.5 mg (as sodium)	Injection	Veletri	AT	EMP	C6123 C6734 C6748 C6762 C6763	1	0	D
Powder for I.V. infusion 1.5 mg (as sodium) with 2 vials diluent 50 mL	Injection	Flolan	GK	EMP	C6123 C6734 C6748 C6762 C6763	1	0	D

1. Schedule 1, entry for Pegfilgrastim  

   Insert:

Ristempa GV EMP C6488 C6489 C6490 C6491 C6492 C6493 C6494 C6501 C6502 C6507 C6512 C6513 C6514 C6515 C6516 C6521 C6522 C6523 C6531 C6532 C6533 C6534 C6535 C6536 C6543 C6544 C6545 C6546 C6554 C6555 1 11 D

1. Schedule 2, after entry for GQ         Insert:

GV Amgen Australia Pty Limited 31 051 057 428

1. Schedule 4 – Patient Contributions

Substitute:

Listed Drug	Form (strength, type, size, etc.)	Manner of Administration	Brand	Pack Quantity	Approved Ex‑manufacturer Price or Proportional Ex‑manufacturer Price $	Claimed price $
Lamivudine	Tablet 100 mg	Oral	Zeffix	28	$55.34	$56.30
Valaciclovir	Tablet 500 mg (as hydrochloride)	Oral	Valtrex	100	$52.40	$52.92